The persons depicted are models used for illustrative purposes only.
Because of the quick progression of meningococcal disease, pre-exposure to antigens may be CRITICAL FOR PROTECTION10
MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections.